Blade Air Mobility to Present at the Ladenburg Thalmann Technology Innovation Expo 25
About Blade Air Mobility
Blade Air Mobility provides air transportation and logistics for hospitals across the United States, where it is one of the largest transporters of human organs for transplant, and for passengers, with helicopter and fixed wing services primarily in the Northeast United States, and Southern Europe. Based in New York City, Blade's asset-light model, coupled with its exclusive passenger terminal infrastructure and proprietary technologies, is designed to facilitate a seamless transition from helicopters and fixed-wing aircraft to Electric Vertical Aircraft ('EVA' or 'eVTOL'), enabling lower cost air mobility that is both quiet and emission-free.
For more information, visit www.blade.com.
Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and may be identified by the use of words such as "will", 'anticipate,' 'believe,' 'could,' 'continue,' 'expect,' 'estimate,' 'may,' 'plan,' 'outlook,' 'future' and 'project' and other similar expressions and the negatives of those terms. These statements, which involve risks and uncertainties, relate to analyses and other information that are based on forecasts of future results and estimates of amounts not yet determinable and may also relate to Blade's future prospects, developments and business strategies. In particular, such forward-looking statements include statements concerning Blade's future financial and operating performance, results of operations, business and capital deployment strategies and plans, customer behavior, competitive position, industry environment and growth opportunities, and the development and adoption of EVA technology. These statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.
Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Blade's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied in forward-looking statements include: our continued incurrence of significant losses; the impact of the COVID-19 pandemic and its related effects, failure of the markets for our offerings to grow as expected, or at all; our ability to effectively market and sell air transportation as a substitute for conventional methods of transportation; the inability or unavailability to use or take advantage of the shift, or lack thereof, to EVA technology; our ability to successfully enter new markets and launch new routes and services; any adverse publicity stemming from accidents involving small aircraft, helicopters or charter flights and, in particular, any accidents involving our third-party operators; the effects of competition; harm to our reputation and brand; our ability to provide high-quality customer support; our ability to maintain a high daily aircraft usage rate; changes in consumer preferences, discretionary spending and other economic conditions; impact of natural disasters, outbreaks and pandemics, economic, social, weather, growth constraints, and regulatory conditions or other circumstances on metropolitan areas and airports where we have geographic concentration; the effects of climate change, including potential increased impacts of severe weather and regulatory activity; the availability of aircraft fuel; our ability to address system failures, defects, errors, or vulnerabilities in our website, applications, backend systems or other technology systems or those of third-party technology providers; interruptions or security breaches of our information technology systems; our placements within mobile applications; our ability to protect our intellectual property rights; our use of open source software; our ability to expand and maintain our infrastructure network; our ability to access additional funding; the increase of costs and risks associated with international expansion; our ability to identify, complete and successfully integrate future acquisitions; our ability to manage our growth; increases in insurance costs or reductions in insurance coverage; the loss of key members of our management team; our ability to maintain our company culture; our reliance on contractual relationships with certain transplant centers and Organ Procurement Organizations; effects of fluctuating financial results; our reliance on third-party operators; the availability of third-party operators; disruptions to third party operators; increases in insurance costs or reductions in insurance coverage for our third-party aircraft operators; the possibility that our third-party aircraft operators may illegally, improperly or otherwise inappropriately operate our branded aircraft; our reliance on third-party web service providers; changes in our regulatory environment; regulatory obstacles in local governments; the expansion of domestic and foreign privacy and security laws; the expansion of environmental regulations; our ability to remediate any material weaknesses or maintain internal controls over financial reporting; our ability to maintain effective internal controls and disclosure controls; changes in the fair value of our warrants; and other factors beyond our control. Additional factors can be found in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, each as filed with the U.S. Securities and Exchange Commission. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, and Blade undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, changes in expectations, future events or otherwise. We are unable to reconciled forward-looking non-GAAP guidance, including Flight Profit Margin, Adjusted Corporate Expenses, and Adjusted EBITDA, without unreasonable effort due to the variability and low visibility with respect to certain costs, the most significant of which are incentive compensation, transaction-related expenses, and certain value measurements, which may have unpredictable, and potentially significant, impact on future GAAP financial results.
ContactsMedia RelationsLee GoldPress@Blade.com
Investor RelationsMat SchneiderInvestors@blade.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Cloud Headwinds Test Confluent's Recovery Case
Confluent (NASDAQ:CFLT) got whacked, dropping over 30% after its Q2 results, and the headlines were led by Stifel pulling the rating to Hold from Buy and trimming its target to $21 from $30. The note called out slowing net new workload activity, weak new customer adds, continued cloud usage optimization, and a big AI-native customer shifting off Confluent Cloud to a self-managed setup as the main reasons the growth story is hitting a rough patch. Warning! GuruFocus has detected 4 Warning Signs with CFLT. That sharp move sparked pushback. Guggenheim said the sell-off was too extreme, acknowledging churn and a dip in net revenue retention to 114% and an implied cloud exit rate of 18%, but still thinking a 4Q exit rate of 21% and subscription exit rate of 19% are doable, implying roughly 21% full-year subscription growth. Needham kept its Buy call (target now $24 from $26), warning the same large AI customer is creating a low-single-digit cloud headwind in late 2025 even as stronger Confluent Platform expectations help offset it and shift cloud mix to 55% of subscription revenue exiting the year. RBC also pushed back, holding Outperform with a $25 target (down from $28), saying the price drop was overdone even though optimizations will temper 2H consumption and point to a roughly 17.5% cloud exit growth rate in Q4. The story is now a tug-of-war between near-term risk and underlying optionality. The market is pricing the pain, but if the AI customer's cadence normalizes and exit rates stabilize, the pullback could look like a setup. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
15 minutes ago
- Yahoo
Morgan Stanley Reaffirms NVIDIA as Top Pick Amid Soaring Chip Demand
NVIDIA Corporation (NASDAQ:NVDA) is one of the . On July 30, Morgan Stanley reiterated the stock as 'Overweight' and raised its price to $200 per share from $170. The analyst noted robust demand for Blackwell chips, which is outpacing supply. Even though supply constraints still persist, the bottleneck will likely ease in the second half of the year. This will, in turn, likely boost earnings. NVIDIA remains Morgan Stanley's top semiconductor pick. 'We think that the increase in enthusiasm for AI semis is justified by long term strength in the business, and raise targets across the board — though some near term constraints remain. PTs higher across the board, stay OW NVDA AVGO ALAB.' NVIDIA Corporation (NASDAQ:NVDA) specializes in AI-driven solutions, providing high-performance GPUs and platforms that power data centers, autonomous vehicles, robotics, and cloud services. While we acknowledge the potential of NVDA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 minutes ago
- Yahoo
Why Regeneron (REGN) Stock Is Trading Up Today
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 3.3% in the morning session after the company reported strong second-quarter financial results that significantly surpassed analyst expectations. The pharmaceutical giant posted earnings per share of $12.89, which crushed the forecast of $8.50. Revenue also beat projections, totaling $3.68 billion against an expected $3.29 billion. This performance marked a notable rebound from the prior quarter. The growth stemmed from strong sales of key treatments, including its eye care therapy Eylea HD, cancer drug Libtayo, and immunology medicine Dupixent, which all recorded substantial sales increases. After the initial pop the shares cooled down to $546.32, up 0.2% from previous close. Is now the time to buy Regeneron? Access our full analysis report here, it's free. What Is The Market Telling Us Regeneron's shares are somewhat volatile and have had 10 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 2 months ago when the stock dropped 19% on the news that the company announced mixed results from its Phase 3 trials for itepekimab, an experimental drug for Chronic Obstructive Pulmonary Disease (COPD). While one trial met its primary endpoint, the other missed, raising concerns about the drug's future and delaying its potential market entry. This setback, likely spooked investors and contributed to the significant decline. Regeneron is down 23.6% since the beginning of the year, and at $546.32 per share, it is trading 54.5% below its 52-week high of $1,202 from August 2024. Investors who bought $1,000 worth of Regeneron's shares 5 years ago would now be looking at an investment worth $846.77. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.